GSK RSV vaccine shows potential to protect adults 50 to 59
A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday.The initial trial results suggest that GSK's shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes...